-+ 0.00%
-+ 0.00%
-+ 0.00%

Palatin Technologies Says BMT-801 Phase 2 Obesity Co-administration Study Met Its Primary Endpoint And Was Highly Statistically Significant

Benzinga·03/31/2025 11:37:29
Listen to the news

The Company reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide and highlighted next steps in its obesity program for its novel next-generation MC4R long-acting peptides and oral small molecules.